Search results for "RESPIRATORY SYSTEM"

showing 10 items of 1829 documents

Functional imaging of airway distensibility

2014

The physiological function of the respiratory system is essential in distending airway smooth muscle and maintaining airway patency. Deep inspirations can reverse contracted airways and protect airways from subsequent bronchospastic stimuli. Obstructive lung diseases may lead to impairment of the beneficial effects of lung inflation through either change in the airway wall or lung parenchyma. Conventional pulmonary function measurements are unable to assess airway stiffness, based on changes in airway size with lung inflation (distensibility). However, high-resolution computed tomography (HRCT) is unique in that it can be used to measure airway distensibility in animals and in humans. Funct…

medicine.medical_specialtyCOPDLungbusiness.industryrespiratory systemSettore MED/10 - Malattie Dell'Apparato Respiratoriomedicine.diseaserespiratory tract diseasesPulmonary function testingFunctional imagingmedicine.anatomical_structuredeep inspirationInternal medicineParenchymamedicineCardiologyRespiratory systemAirwaybusinessAsthma
researchProduct

2017

T1 maps have been shown to yield useful diagnostic information on lung function in patients with chronic obstructive pulmonary disease (COPD) and asthma, both for native T1 and ΔT1, the relative reduction while breathing pure oxygen. As parameter quantification is particularly interesting for longitudinal studies, the purpose of this work was both to examine the reproducibility of lung T1 mapping and to compare T1 found in COPD and asthma patients using IRSnapShotFLASH embedded in a full MRI protocol. 12 asthma and 12 COPD patients (site 1) and further 15 COPD patients (site 2) were examined on two consecutive days. In each patient, T1 maps were acquired in 8 single breath-hold slices, brea…

medicine.medical_specialtyCOPDMultidisciplinaryLungbusiness.industrymedicine.diseaserespiratory tract diseases030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinemedicine.anatomical_structure030228 respiratory systemInternal medicineRespirationBreathingRoom air distributionCardiologyMedicinebusinessProspective cohort studyPerfusionAsthmaPLOS ONE
researchProduct

<p>Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting&lt…

2019

Background Patients with chronic obstructive pulmonary disease (COPD) show signs of reduced physical activity from the early stages of the disease, impacting morbidity and mortality. Data suggest treatment with tiotropium, a long-acting muscarinic antagonist, and olodaterol, a long-acting s2-agonist (LABA), as monotherapies and in combination, increases exercise capacity. This study assessed the effects of fixed-dose tiotropium/olodaterol (delivered via Respimat®) on physical function in Global Initiative for Chronic Obstructive Lung Disease A-D patients requiring long-acting dual bronchodilation treatment in a real-world setting. Methods This open-label, single arm, noninterventional study…

medicine.medical_specialtyCOPDRespimatbusiness.industryOlodaterolGeneral Medicinemedicine.diseaseConfidence intervalObstructive lung disease03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePatient satisfaction030228 respiratory systemchemistryInternal medicinemedicineClinical endpoint030212 general & internal medicineAdverse effectbusinessInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Long-term safety of tiotropium/olodaterol Respimat<sup>®</sup> in patients with moderate-to-very severe COPD and renal i…

2018

Introduction: The safety, lung function efficacy, and symptomatic benefits of combined tiotropium and olodaterol in patients with COPD were established in the 1-year TONADO (R) studies (NCT01431274; NCT01431287). As tiotropium is predominantly excreted by the kidneys, the long-term safety profile of tiotropium/olodaterol was investigated in patients with renal impairment in a prespecified safety analysis of the TONADO studies. Methods: These were 2 replicate, randomized, double-blind, parallel-group, 52-week Phase III studies that assessed tiotropium/olodaterol compared with tiotropium or olodaterol alone (all via Respimat (R)) in patients with moderate-to-very severe COPD. In this analysis…

medicine.medical_specialtyCOPDRespimatmedicine.drug_classbusiness.industryUrinary systemOlodaterolUrologyRenal functionGeneral Medicinemedicine.disease03 medical and health scienceschemistry.chemical_compound0302 clinical medicine030228 respiratory systemTolerabilitychemistryAnticholinergicmedicine030212 general & internal medicineAdverse effectbusinessInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Pharmacotherapy of COPD in Central and Eastern Europe - The POPE study

2016

Introduction: In Central and Eastern Europe (CEE) the burden of chronic obstructive pulmonary disease (COPD) is high. It remains unknown whether patients are treated in line with GOLD recommendations or according to their phenotypes. Our aim was to analyze the treatment patterns of COPD in CEE. Methods: In the frame of the POPE study (ClinicalTrials.gov - NCT02119494) data including pharmacotherapy were collected in patients with stable COPD across 11 CEE countries. Results: 3366 patients (66±9 yrs, 70% male, FEV 1 53±18%) participated in the study. In all GOLD categories, the most widely used medications were long-acting beta-2 agonists (LABA), followed by long-acting antimuscarinic agents…

medicine.medical_specialtyCOPDbiologyExacerbationbusiness.industryPulmonary diseaseInhaled corticosteroidsOverlap syndromeLamabiology.organism_classificationmedicine.disease3. Good health03 medical and health sciences0302 clinical medicinePharmacotherapy030228 respiratory systemInternal medicinePhysical therapyMedicineIn patient030212 general & internal medicinebusinesshormones hormone substitutes and hormone antagonists1.12 Clinical Problems - COPD
researchProduct

<p>Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO<sup>®</sup> and…

2016

BACKGROUND Increasing age is associated with poor prognosis in patients with COPD. OBJECTIVE This analysis from the replicate Phase III OTEMTO® and TONADO® studies examined the efficacy and safety of tiotropium, a long-acting anticholinergic, combined with olodaterol, a long-acting β2-agonist, compared to monotherapies and placebo in patients with COPD aged 40 years to <65 years, 65 years to <75 years, 75 years to <85 years, and ≥85 years. METHODS In these double-blind, parallel-group, active-controlled, multicenter, randomized studies, patients received tiotropium + olodaterol 2.5/5 μg or 5/5 μg, tiotropium 5 μg or 2.5 μg (TONADO only), olodaterol 5 μg (TONADO only), or placebo (OTEMTO onl…

medicine.medical_specialtyCOPDbusiness.industrymedicine.drug_classOlodaterolArea under the curveSubgroup analysisGeneral MedicinePlacebomedicine.diseaseRescue medicationrespiratory tract diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicine030228 respiratory systemchemistryInternal medicineAnticholinergicMedicineIn patient030212 general & internal medicinebusinessInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Cationic lipide mediated transfer of c-abl and bcr antisense oligonucleotides to immature normal myeloid cells: Uptake, biological effects and modula…

1996

Uptake and biochemical and biological effects of antisense oligodeoxynucleotides (ODN) specific for c-abl and bcr genes were studied in normal immature myeloid cells. CD34-positive cells were purified by positive and negative selection and cultured in liquid culture for 7 days. These cells were then incubated with ODNs, either alone or in combination with cationic lipids. The uptake of ODNs was enhanced by the use of cationic lipids. In addition, very low concentrations of ODNs in combination with cationic lipids were capable of specifically inhibiting the expression of the c-abl gene. In contrast, no effects were seen on the expression of bcr. However, despite the effective blocking of c-a…

medicine.medical_specialtyCell Membrane PermeabilityChemical PhenomenaMolecular Sequence DataRibonuclease HAntigens CD34BiologyTransfectionPolymerase Chain ReactionCationsProto-Oncogene Proteinshemic and lymphatic diseasesInternal medicineGene expressionmedicineHumansCation Exchange ResinsRNA NeoplasmProto-Oncogene Proteins c-ablGeneCells CulturedOncogene ProteinsABLHematologyBase SequenceCell-Free SystemChemistry PhysicalCell growthCationic polymerizationbreakpoint cluster regionBiological Transporthemic and immune systemsHematologyGeneral MedicineOligonucleotides AntisenseProtein-Tyrosine Kinasesrespiratory systemHematopoietic Stem CellsLipidsMolecular biologyHaematopoiesisGene Expression RegulationDepression ChemicalLiposomesProto-Oncogene Proteins c-bcrAnnals of Hematology
researchProduct

A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19

2020

Purpose COVID-19 (coronavirus disease 2019) is a public health emergency of international concern. As of this time, there is no known effective pharmaceutical treatment, although it is much needed for patient contracting the severe form of the disease. The aim of this systematic review was to summarize the evidence regarding chloroquine for the treatment of COVID-19. Methods PubMed, EMBASE, and three trial Registries were searched for studies on the use of chloroquine in patients with COVID-19. Results We included six articles (one narrative letter, one in-vitro study, one editorial, expert consensus paper, two national guideline documents) and 23 ongoing clinical trials in China. Chloroqui…

medicine.medical_specialtyChinaCoronaviruPneumonia ViralPsychological interventionMEDLINEDiseaseCritical Care and Intensive Care MedicineWorld Health OrganizationArticle03 medical and health sciencesAntimalarialsBetacoronavirus0302 clinical medicineChloroquinePandemicmedicineHumansIntensive care medicinePandemicsClinical Trials as Topicbusiness.industrySARS-CoV-2Public healthCOVID-19030208 emergency & critical care medicineChloroquinePneumoniaCOVID-19 Drug TreatmentClinical trialCoronavirusClinical researchTreatment Outcome030228 respiratory systembusinessCoronavirus Infectionsmedicine.drugJournal of Critical Care
researchProduct

Relaxation by Calcium Antagonists of Potassium-contracted Trachea from Normal and Sensitized Guinea-pigs: Influence of Epithelium and the Surface of …

1993

Abstract A technique by which drug access was restricted to either the mucosal or the adventitial surface of tracheal rings, isolated from normal (unsensitized) or sensitized guinea-pigs, was used to study the role of the epithelium in the relaxation produced by calcium antagonists (verapamil, nifedipine, cinnarizine and flunarizine) of K+-induced contraction. In trachea from normal guinea-pigs, the relaxation to verapamil for unrestricted or mucosal drug entry was reduced in the absence of epithelium, whereas the relaxation produced by nifedipine, cinnarizine or flunarizine was unchanged. In sensitized trachea, the relaxation elicited by the calcium antagonists tested was similar in intact…

medicine.medical_specialtyContraction (grammar)CinnarizineSurface PropertiesMuscle RelaxationFreund's AdjuvantGuinea PigsPharmaceutical Sciencechemistry.chemical_elementIn Vitro TechniquesCalciumEpitheliumCinnarizineGuinea pigNifedipineInternal medicineRespiratory HypersensitivitymedicineAnimalsFlunarizinePharmacologyMuscle SmoothSerum Albumin Bovinerespiratory systemCalcium Channel BlockersEpitheliumTracheaKineticsEndocrinologymedicine.anatomical_structurechemistryPotassiumVerapamilMuscle Contractionmedicine.drugJournal of Pharmacy and Pharmacology
researchProduct

Human corticotropin-releasing hormone and thyrotropin-releasing hormone modulate the hypercapnic ventilatory response in humans

1996

Human corticotropin-releasing hormone (hCRH) and thyrotropin-releasing hormone (TRH) are known to stimulate ventilation after i.v. administration in humans. In a placebo-controlled, single-blind study we aimed to clarify if both peptides act by altering central chemosensitivity. Two subsequent CO2-rebreathing tests were performed in healthy young volunteers. During the first test 0.9% NaCl was given i.v.; during the second test 200 micrograms of hCRH (n = 12) or 400 micrograms of TRH (n = 6) was administered i.v. Nine subjects received 0.9% NaCl i.v. during both rebreathing manoeuvres. The CO2-response curves for the two tests were compared within the same subject. In the hCRH group a marke…

medicine.medical_specialtyCorticotropin-Releasing HormoneClinical BiochemistryThyrotropin-releasing hormonePeptide hormoneBiochemistryHypercapniaPlacebos03 medical and health sciencesCorticotropin-releasing hormone0302 clinical medicineTachycardiaInternal medicineFlushingmedicineHumansSingle-Blind MethodRespiratory systemThyrotropin-Releasing HormoneLung function030304 developmental biology0303 health sciencesbusiness.industryRespirationGeneral MedicineCarbon DioxideRespiratory Function TestsEndocrinologyBreathingbusiness030217 neurology & neurosurgeryHormoneEuropean Journal of Clinical Investigation
researchProduct